DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
S•••••• A• L•
Pharmaceuticals, Biotechnology and Life Sciencesgroup grade Bon a schedule nowsponsor unattributed
Also written as: S•••••• A• - Holdco
Nothing material in the last 200 days. No dated change on record yet.
Mark path, consensus per quarter end
118¢ · 118¢ · 116¢ · 116¢ · 115¢Q2 2025 to Q2 2026
Where each lender marks it, 6 points apart
109¢115¢
Principal held
at least $9.4M
sum of BDC pieces, a lower bound
Fair value
$11.8M
115c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
2
2 on the latest quarter
Facilities
3
1 equity pieces beside them
Next maturity
Feb 29, 2032
no dated debt inside 24 months
On the tape since
Mar 31, 2025
latest Jun 30, 2026
Events
1
dated, non-routine
Lender marks
each lender's own fair value over cost at Jun 30, 2026, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| C••••••• P•••••• C••••• I••••• C••• | $9.13M | 115¢ | -1 pts |
| M•• I••••••••• C•••• | $295K | 109¢ | -1 pts |
Every BDC piece · 4 positions across 2 lenderslargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| C••••••• P•••••• C••••• I••••• C••• | term loan first lien Investment T••• S••••• S•••••• F•••• L••• T••• L••• I••••••• T••• SR + 550, 75 F•••• I•••• | $9.1M | $11.4M 115c | SOFR+550 bp |
| M•• I••••••••• C•••• | notes unsecured or subordinated S••••••••• D••• N••• R•••••••• R••• and S••••• N/A I••••••• R••• F•••• N/A I••••••• R••• 1 | $295,000 | $358,000 109c | PIK 12.50% |
| C••••••• P•••••• C••••• I••••• C••• | revolver first lien Investment T••• R••••••• E••••••••• D••• 2/27/2032 | Not disclosed | Not disclosed | |
| C••••••• P•••••• C••••• I••••• C••• | revolver first lien Investment T••• S••••• S•••••• F•••• L••• R••••••• M•••••••/ D••••••••• D••• 02/2032 | Not disclosed | Not disclosed n/a | S+550 bp |
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien | at least $9.1M | 115c | SOFR+550 bp | Feb 29, 2032 | 1 |
| unsecured or subordinated notes unsecured or subordinated | at least $295,000 | 109c | PIK 12.50% | Feb 28, 2033 | 1 |
| first lien revolver first lien | unknown | n/a | S+550 bp | Feb 29, 2032 | 1 |
Equity pieces beside the debt: other ($10.2M fair value, 1 BDC)
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 2 | $9.4M | $11.8M | 115c | 1 |
| Mar 31, 2026 | 2 | $9.4M | $11.9M | 116c | 1 |
| Dec 31, 2025 | 2 | $23.5M | $23.6M | 117c | 1 |
| Sep 30, 2025 | 2 | $11.8M | $12.1M | 118c | 1 |
All 6 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2025 | 2 | $11.9M | $12.1M | 118c | 1 |
| Mar 31, 2025 | 2 | $10.7M | $10.4M | 102c | 1 |
What changed
- New borrower on a BDC scheduleMar 31, 2025
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- SOLVIASderivedthe codename stem after legal suffixes and deal words
- Spellings
- 2 across 2 BDCsderived
- Industry
- Pharmaceuticals, Biotechnology and Life Sciencesreportedas one filer wrote it